Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Antiarrhythmic Drugs Market

Antiarrhythmic Drugs Market Share

Report ID: GMI12134
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Antiarrhythmic Drugs Market Share

The market is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A key aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Antiarrhythmic Drugs Market Companies

Some of the eminent market participants operating in the antiarrhythmic drugs industry include:

Abbott Laboratories
Astellas Pharma
AstraZeneca
Baxter International
Bayer AG
Bristol-Myers Squibb
GlaxoSmithKline
Johnson & Johnson
Milestone Pharmaceuticals
Novartis
Pfizer
Sanofi
Teva Pharmaceutical Industries
Upsher-Smith Laboratories
Viatris

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global antiarrhythmic drugs industry was valued at approximately USD 1 billion in 2023 and is estimated to grow at a 6% CAGR from 2024 to 2032, driven by the increasing prevalence of cardiovascular diseases.

The beta blockers (Class II) segment dominated the market with a revenue of USD 326.4 million in 2023, primarily due to the rising prevalence of hypertension and arrhythmias.

The antiarrhythmic drugs market in the U.S. was valued at USD 420.5 billion in 2023 and is expected to grow at a CAGR of 6.1% over the forecast period, driven by the aging population and increasing incidence of atrial fibrillation.

Key players in the market include Abbott Laboratories, Astellas Pharma, AstraZeneca, Baxter International, Bayer AG, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Milestone Pharmaceuticals, Novartis, and Pfizer.